Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cross

Showing results (581-590 of 595) with videos related to

Pageof 60
Sort By:
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2018
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Roxanne V Andaya, Lennart T Anger, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Blood Advances|November 14, 2022
CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison, et al.
Blood|March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMTNicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
The New England Journal of Medicine|October 15, 2011
Somatic SF3B1 mutation in myelodysplasia with ring sideroblastsE Papaemmanuil, M Cazzola, J Boultwood, et al.
Regulatory Toxicology and Pharmacology : RTP|July 5, 2020
Skin sensitization in silico protocolCandice Johnson, Ernst Ahlberg, Lennart T Anger, et al.
The New England Journal of Medicine|December 12, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2J Nangalia, C E Massie, E J Baxter, et al.
Leukemia|April 26, 2016
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International ScaleN C P Cross, H E White, T Ernst, et al.
Pageof 60

Showing results (581-590 of 595) with videos related to

Sort By:
Pageof 60
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2018
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Roxanne V Andaya, Lennart T Anger, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Blood Advances|November 14, 2022
CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño-Tarragona, Alberto Álvarez-Larrán, Claire Harrison, et al.
Blood|March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMTNicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
The New England Journal of Medicine|October 15, 2011
Somatic SF3B1 mutation in myelodysplasia with ring sideroblastsE Papaemmanuil, M Cazzola, J Boultwood, et al.
Regulatory Toxicology and Pharmacology : RTP|July 5, 2020
Skin sensitization in silico protocolCandice Johnson, Ernst Ahlberg, Lennart T Anger, et al.
The New England Journal of Medicine|December 12, 2013
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2J Nangalia, C E Massie, E J Baxter, et al.
Leukemia|April 26, 2016
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International ScaleN C P Cross, H E White, T Ernst, et al.
Pageof 60